European Journal of Clinical Pharmacology

, Volume 9, Issue 4, pp 291–298 | Cite as

Pharmacokinetics of lofepramine in man: Relationship to inhibition of noradrenaline uptake

  • G. Plym Forshell
  • B. Siwers
  • J. R. Tuck


The pharmacokinetics of lofepramine, an imipramine analogue, have been studied by administering single oral doses to volunteers, determination of plasma levels of lofepramine and desmethylimipramine after ten days of oral administration to patients, and by relating plasma levels to the effect on uptake of noradrenaline by isolated rat irides and brain slices of plasma samples collected during treatment. The results indicate that lofepramine undergoes pronounced first pass elimination and that desmethylimipramine is a major metabolite of it. During steady-state conditions the plasma level of lofepramine fluctuates considerably between doses. A linear relation was found between inhibition of neuronal uptake of noradrenaline and the plasma concentration of desmethylimpramine. No effect was seen on the uptake of 5-hydroxytryptamine in brain slices incubated in patients' plasma which suggests that neither lofepramine nor its metabolites formedin vivo in man affect neuronal uptake of this amine. Lofepramine belongs to the group of tricyclic anti-depressants which preferentially inhibit noradrenaline uptake.

Key words

Tricyclic antidepresent lofepramine single- and multiple-dose kinetics noradrenaline and 5-hydroxytryptamine uptake man 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alexanderson, B.: Pharmacokinetics of nortriptyline in man after single and multiple oral doses: the predictability of steady-state plasma concentrations from single dose plasma-level data. Europ. J. clin. Pharmacol.4, 82–91 (1972 a)Google Scholar
  2. 2.
    Alexanderson, B.: Pharmacokinetics of desmethylimipramine and nortriptyline in man after single and mutiple oral doses — a cross-over study. Europ. J. clin. Pharmacol.5, 1–10 (1972 b)Google Scholar
  3. 3.
    Borgå, O., Azarnoff, D.L., Plym Forshell, G., Sjöqvist, F.: Plasma protein binding of tricyclic antidepressants in man. Biochem. Pharmacol.18, 2135–2143 (1969)Google Scholar
  4. 4.
    Borgå, O., Hamberger, B., Malmfors, T., Sjöqvist, F.: The role of plasma protein binding for the inhibitory effect of nortriptyline on the neuronal uptake of noradrenaline. Clin. Pharmacol. Ther.11, 581–588 (1970)Google Scholar
  5. 5.
    Eriksoo, E., Rohte, O.: On the chemistry and pharmacology of a new potential antidepressant, Leo 640. Arzneimittel-Forsch.20, 1561–1569 (1970)Google Scholar
  6. 6.
    Ervik, M., Walle, T., Ehrsson, H.: Quantitative gas chromatographic determination of nanogram levels of desipramine in serum. Acta pharm. suecica7, 625–634 (1970)Google Scholar
  7. 7.
    Freyschuss, U., Sjöqvist, F., Tuck, J.R.: Tyramine pressor effects in man before and during treatment with nortriptyline or ECT: correlation between pharmacokinetics and effect of nortriptyline. Pharmacol. Clin.2, 72–78 (1970)Google Scholar
  8. 8.
    Hamberger, B., Tuck, J.R.: Effect of tricyclic antidepressants on the uptake of noradrenaline and 5-hydroxytryptamine by rat brain slices incubated in buffer or human plasma. Europ. J. clin. Pharmacol.5, 229–235 (1973)Google Scholar
  9. 9.
    Hamberger, B., Tuck, J.R.:3H-nortriptyline uptake and tissue-bindingin vitro and its effect on3H-noradrenaline uptake. Experientia (Basel) (accepted for publication 1975)Google Scholar
  10. 10.
    Jonsson, G., Hamberger, B., Malmfors, T., Sachs, C.: Uptake and accumulation of3H-noradrenaline in adrenergic nerves of rat iris, effect of reserpine, monoamine oxidase and tyrosine hydroxylase inhibition. Europ. J. Pharmacol.8, 58–72 (1969)Google Scholar
  11. 11.
    Jørgensen, A.: A gas chromatographic method for the determination of amitriptyline and nortriptyline in human serum. Acta pharmacol. (Kbh.)36, 79–90 (1975)Google Scholar
  12. 12.
    Plym Forshell, G.: Studies on the distribution and excretion of (3H14C) labelled lofe-pramine in the rat. Xenobiotica5, 73–82 (1975)Google Scholar
  13. 13.
    Siwers, B., Tuck, J.R., Freyschuss, U., Azarnoff, D.L., Sjöqvist, F.: A novel approach to the phase-I clinical trial of tricyclic antidepressant drugs. In: Abstracts for Fourth International Congress of Pharmacology, July 14 – 18, 1969, pp 432–433, Basel Switzerland. Basel: Schwabe & Co. 1969Google Scholar
  14. 14.
    Siwers, B., Freyschuss, U., Hamberger, B., Tuck, J.R., Malmfors, T., Sjöqvist, F.: A quantitative approach to the initial clinical trial of tricyclic antidepressants: a comparison of Leo 640 and nortriptyline. Europ. J. clin. Pharmacol.3, 12–17 (1970)Google Scholar
  15. 15.
    Sjöqvist, F.: A pharmacokinetic approach to the treatment of depression. Int. Pharmacopsychiat.6, 147–169 (1971)Google Scholar
  16. 16.
    Tuck, J.R., Kahan, E., Siwers, B.: Biological and pharmacokinetic evidence for generic equivalence of three imipramine preparations: comparison with a new imipramine analogue. Acta pharmacol. (Kbh.)32, 304–313 (1973)Google Scholar
  17. 17.
    Tuck, J.R., Punell, G.: Uptake of (3H) 5-hydroxytryptamine and (3H) noradrenaline by slices of rat brain incubated in plasma from patients treated with chlorimipramine, imipramine or amitriptyline. J. pharm. Sci.25, 573–574 (1973)Google Scholar
  18. 18.
    Åsberg, M., Bertilsson, L., Tuck, J.R., Cronholm, B., Sjöqvist, F.: Indolemine metabolites in the cerebro-spinal fluid of depressed patients before and during treatment with nortriptyline. Clin. Pharmacol. Ther.14, 277–286 (1973)Google Scholar

Copyright information

© Springer-Verlag 1976

Authors and Affiliations

  • G. Plym Forshell
    • 1
    • 2
  • B. Siwers
    • 1
    • 2
  • J. R. Tuck
    • 1
    • 2
  1. 1.Research Laboratories, AB LeoHelsingborgSweden
  2. 2.Dept. of Clinical Pharmacology and PsychiatryHuddinge HospitalHuddingeSweden

Personalised recommendations